Transmitted HIV drug resistance in treatment‐naive Romanian patients

Transmitted HIV drug resistance (TDR) remains an important concern for individuals unexposed to antiretroviral treatment. Data on the prevalence of TDR, available mainly for HIV‐1 subtype B, are now also emerging for other subtypes. In Romania, a steady predominance of subtype F was reported among both long‐term survivor children and newly infected adults. The pol gene of 61 drug‐naïve patients infected with HIV, diagnosed between 1997 and 2011 was sequenced in order to analyze the prevalence of primary resistance mutations and to correlate these with the infecting genotype. Only 5/61 specimens were classified as infected recently using the BED‐Capture Enzyme Immunoassay. Subtype F1 was prevalent (80.3%), however, other HIV‐1 clades are increasingly identified, especially in the group of subjects infected recently. An HIV transmission cluster, associated to injecting drug use was identified by phylogenetic analysis. The overall prevalence of TDR was 14.75%, mainly associated with NRTI resistance (13.11%), TAMs and M184V being the most common mutations. A declining trend of TDR was recorded from 26.08% in 1997–2004 to 7.89% in 2005–2011. No primary resistance was identified among recent seroconvertors. All HIV‐1 strains had minor mutations in the protease and RT genes, often detected at polymorphic positions. The declining rates of TDR might be related to the high efficacy of HAART and to the increasing number of treated patients with virological success who have a low risk of transmission. The recent increase of HIV‐1 infections which involve other subtypes impose a continuous surveillance of the genetic composition of the epidemic. J. Med. Virol. 85:1139–1147, 2013. © 2013 Wiley Periodicals, Inc.

[1]  G. Magiorkinis,et al.  Molecular typing of the recently expanding subtype B HIV-1 epidemic in Romania: Evidence for local spread among MSMs in Bucharest area , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[2]  P. Narciso,et al.  Ultra‐deep sequencing reveals hidden HIV‐1 minority lineages and shifts of viral population between the main cellular reservoirs of the infection after therapy interruption , 2012, Journal of medical virology.

[3]  A. De Luca,et al.  High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype. , 2012, The Journal of antimicrobial chemotherapy.

[4]  F. Wit,et al.  Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. , 2012, The Lancet. Infectious diseases.

[5]  Á. Holguín,et al.  Increase of Transmitted Drug Resistance among HIV-Infected Sub-Saharan Africans Residing in Spain in Contrast to the Native Population , 2011, PloS one.

[6]  A. Hatzakis,et al.  HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  J. Vingerhoets,et al.  Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine , 2011, Journal of acquired immune deficiency syndromes.

[8]  M. Leal,et al.  Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010 , 2011, Virology Journal.

[9]  M. Poljak,et al.  European recommendations for the clinical use of HIV drug resistance testing: 2011 update. , 2011, AIDS reviews.

[10]  D. Pillay,et al.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load , 2010, AIDS.

[11]  R. Swanstrom,et al.  A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia. , 2010, The Journal of infectious diseases.

[12]  W. Heneine,et al.  Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006 , 2010, AIDS.

[13]  M. Poljak,et al.  Transmission of drug-resistant HIV-1 is stabilizing in Europe. , 2009, The Journal of infectious diseases.

[14]  N. Taveira,et al.  Antiretroviral Drug Resistance Surveillance among Treatment-Naive Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance , 2009, Antimicrobial Agents and Chemotherapy.

[15]  A. Vicente,et al.  Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates , 2009, Retrovirology.

[16]  C. Delaugerre,et al.  Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996–2006 in France , 2009, AIDS.

[17]  Anne-Mieke Vandamme,et al.  Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.

[18]  Christopher H Woelk,et al.  A public health model for the molecular surveillance of HIV transmission in San Diego, California , 2009, AIDS.

[19]  D. Pillay,et al.  O112 Trends in transmitted HIV drug resistance among non-B subtypes in the UK , 2008 .

[20]  Robert W Shafer,et al.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. , 2008, AIDS reviews.

[21]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.

[22]  Mark Myatt,et al.  Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment , 2008, Antiviral therapy.

[23]  L. Bacheler,et al.  Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. , 2007, Journal of virological methods.

[24]  D. Richman,et al.  Update of the drug resistance mutations in HIV-1: 2007. , 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[25]  John P. Walsh,et al.  Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom , 2007, AIDS.

[26]  D. Otelea,et al.  Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[27]  C. Pilcher,et al.  Diagnosis and management of acute HIV infection. , 2007, Infectious disease clinics of North America.

[28]  R. Shafer,et al.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.

[29]  Ingrid A. Beck,et al.  Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency , 2006, Journal of Clinical Microbiology.

[30]  L. Stuyver,et al.  Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[32]  V. Calvez,et al.  Clinically Relevant Genotype Interpretation of Resistance to Didanosine , 2005, Antimicrobial Agents and Chemotherapy.

[33]  Matthew J. Gonzales,et al.  Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.

[34]  M. Peeters,et al.  Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected With Non-B HIV-1 Variants and Matched Patients Infected With HIV-1 Subtype B , 2004, Journal of acquired immune deficiency syndromes.

[35]  S. Hetherington,et al.  Antiviral Efficacy of Abacavir in Antiretroviral Therapy-Experienced Adults Harbouring HIV-1 with Specific Patterns of Resistance to Nucleoside Reverse Transcriptase Inhibitors , 2004, Antiviral therapy.

[36]  Maureen M Goodenow,et al.  Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. , 2003, Biochemistry.

[37]  Colombe Chappey,et al.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.

[38]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[39]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[40]  Diana D. Huang,et al.  Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. , 2002, AIDS research and human retroviruses.

[41]  S. Hammer,et al.  The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.

[42]  J. Fantini,et al.  Mutation Patterns of the Reverse Transcriptase and Protease Genes in Human Immunodeficiency Virus Type 1-Infected Patients Undergoing Combination Therapy: Survey of 787 Sequences , 1999, Journal of Clinical Microbiology.

[43]  J. Martinez-Picado,et al.  Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.

[44]  D. Richman,et al.  Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. , 1998, AIDS Research and Human Retroviruses.

[45]  T. Merigan,et al.  Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy , 1996, Journal of virology.

[46]  E. Arnold,et al.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Ruță,et al.  The serologic significance of F viral genotype for human immunodeficiency virus type 1 epidemic. , 1994, The Journal of infectious diseases.

[48]  J. Durham THE CHANGING HIV/AIDS EPIDEMIC , 1994, Nursing Clinics of North America.

[49]  M Slatkin,et al.  A cladistic measure of gene flow inferred from the phylogenies of alleles. , 1989, Genetics.

[50]  K. Mandaliya,et al.  Drug-resistant HIV-1 in sub-Saharan Africa: clinical and public health studies , 2013 .

[51]  M. Soares,et al.  Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[52]  S. Ruță,et al.  Dynamics of the HIV-1 variability in adults from Bucharest, 1992-1998. , 1999, Romanian journal of virology.

[53]  R. Hudson,et al.  A statistical test for detecting geographic subdivision. , 1992, Molecular biology and evolution.

[54]  S. Hammer,et al.  Antiretroviral Drug Resistance Testing in Adult Hiv-1 Infection: 2008 Recommendations of an International Aids Society–usa Panel , 2022 .